Advertisement
Research Article

Transcriptional Profiling of the Dose Response: A More Powerful Approach for Characterizing Drug Activities

  • Rui-Ru Ji mail,

    ruiruji@gmail.com

    Affiliation: Bristol-Myers Squibb Research and Development, Princeton, New Jersey, United States of America

    X
  • Heshani de Silva,

    Affiliation: Bristol-Myers Squibb Research and Development, Princeton, New Jersey, United States of America

    X
  • Yisheng Jin,

    Affiliation: Johnson Graduate School of Management, Cornell University, Ithaca, New York, United States of America

    X
  • Robert E. Bruccoleri,

    Affiliation: Congenomics, Glastonbury, Connecticut, United States of America

    X
  • Jian Cao,

    Affiliation: Bristol-Myers Squibb Research and Development, Princeton, New Jersey, United States of America

    X
  • Aiqing He,

    Affiliation: Bristol-Myers Squibb Research and Development, Princeton, New Jersey, United States of America

    X
  • Wenjun Huang,

    Affiliation: Bristol-Myers Squibb Research and Development, Princeton, New Jersey, United States of America

    X
  • Paul S. Kayne,

    Affiliation: Bristol-Myers Squibb Research and Development, Princeton, New Jersey, United States of America

    X
  • Isaac M. Neuhaus,

    Affiliation: Bristol-Myers Squibb Research and Development, Princeton, New Jersey, United States of America

    X
  • Karl-Heinz Ott,

    Affiliation: Bristol-Myers Squibb Research and Development, Princeton, New Jersey, United States of America

    X
  • Becky Penhallow,

    Affiliation: Bristol-Myers Squibb Research and Development, Princeton, New Jersey, United States of America

    X
  • Mark I. Cockett,

    Affiliation: Bristol-Myers Squibb Research and Development, Princeton, New Jersey, United States of America

    X
  • Michael G. Neubauer,

    Affiliation: Bristol-Myers Squibb Research and Development, Princeton, New Jersey, United States of America

    X
  • Nathan O. Siemers,

    Affiliation: Bristol-Myers Squibb Research and Development, Princeton, New Jersey, United States of America

    X
  • Petra Ross-Macdonald

    Affiliation: Bristol-Myers Squibb Research and Development, Princeton, New Jersey, United States of America

    X
  • Published: September 18, 2009
  • DOI: 10.1371/journal.pcbi.1000512

About the Authors

Rui-Ru Ji, Heshani de Silva, Jian Cao, Aiqing He, Wenjun Huang, Paul S. Kayne, Isaac M. Neuhaus, Karl-Heinz Ott, Becky Penhallow, Mark I. Cockett, Michael G. Neubauer, Nathan O. Siemers, Petra Ross-Macdonald
Bristol-Myers Squibb Research and Development, Princeton, New Jersey, United States of America
Yisheng Jin
Johnson Graduate School of Management, Cornell University, Ithaca, New York, United States of America
Robert E. Bruccoleri
Congenomics, Glastonbury, Connecticut, United States of America

Corresponding Author

Email: ruiruji@gmail.com

Competing Interests

The authors are current and previous employees of Bristol-Myers Squibb, who is the manufacturer of dasatinib (one of the compounds included in the study).

Author Contributions

Performed the experiments: HdS JC AH WH BP. Analyzed the data: RRJ YJ KHO PRM. Contributed reagents/materials/analysis tools: RRJ REB PSK IMN MIC NOS. Wrote the paper: RRJ PRM. Developed the analytical methods described in the manuscript: RRJ. Designed the experiments: HdS. Revised the manuscript: YJ REB KHO NOS. Conceived transcriptional dose response concept: MGN.